Japanese drug major Astellas held an R&D meeting this month, at which it said that projects are in progress as expected. The principal R&D targets include the maximization of product value on a global basis, speedy development and launch of new products and improvement of profitability in R&D investments.
The management expressed the hope of achieving the mid-term plan formulated in November 2005 with a target operating income of 250.0 billion yen ($2.2 billion) in the fiscal year ending March 2008 (against 193.0 billion yen in that ended March 2006) through enhancement of R&D activities and cost-cutting efforts.
Priority projects
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze